Design and Preliminary Immunogenicity Evaluation of Nipah Virus Glycoprotein G Epitope-Based Peptide Vaccine in Mice., PMID:40333318
A monoclonal antibody targeting the Nipah virus fusion glycoprotein apex imparts protection from disease., PMID:39240113
An in vivo BSL-2 model for henipavirus infection based on bioluminescence imaging of recombinant Cedar virus replication in mice., PMID:38770087
Computer-assisted identification of potential quinolone derivatives targeting Nipah virus glycoprotein attachment with human cell surface receptor ephrin-B2: Multistep virtual screening., PMID:37442011
Assessment of the immunogenicity and protection of a Nipah virus soluble G vaccine candidate in mice and pigs., PMID:36274696
Computational Identification of Potential Multitarget Inhibitors of Nipah Virus by Molecular Docking and Molecular Dynamics., PMID:35744699
Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates., PMID:34696372
Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy., PMID:32933033
Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches., PMID:32377531
Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study., PMID:32027842
A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection., PMID:31686101
Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities., PMID:30866781
Generation of therapeutic antisera for emerging viral infections., PMID:30323953
Two highly similar LAEDDTNAQKT and LTDKIGTEI epitopes in G glycoprotein may be useful for effective epitope based vaccine design against pathogenic Henipavirus., PMID:26970211
Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection., PMID:25392218
Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction., PMID:23698741
Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo., PMID:23192877
Nipah virus infection and glycoprotein targeting in endothelial cells., PMID:21054904
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection., PMID:19888339
Ephrin-B2 expression critically influences Nipah virus infection independent of its cytoplasmic tail., PMID:19108727
Evidence of a potential receptor-binding site on the Nipah virus G protein (NiV-G): identification of globular head residues with a role in fusion promotion and their localization on an NiV-G structural model., PMID:16840334
Henipaviruses: recent observations on regulation of transcription and the nature of the cell receptor., PMID:15119767
Potent Cross-neutralizing Antibodies Reveal Vulnerabilities of Henipavirus Fusion Glycoprotein., PMID:40298900
Structural biology of Nipah virus G and F glycoproteins: Insights into therapeutic and vaccine development., PMID:40261700
Serological and molecular analysis of henipavirus infections in synanthropic fruit bat and rodent populations in the Centre and North regions of Cameroon (2018-2020)., PMID:39994638
Malaysia outbreak survivors retain detectable Nipah antibodies and memory B cells after 25 years., PMID:39755279
Functional assessment of the glycoproteins of a novel Hendra virus variant reveals contrasting fusogenic capacities of the receptor-binding and fusion glycoproteins., PMID:39704501
Establishing an immune correlate of protection for Nipah virus in nonhuman primates., PMID:39702562
Immunogenicity and Neutralization of Recombinant Vaccine Candidates Expressing F and G Glycoproteins against Nipah Virus., PMID:39340029
Ferritin nanoparticle-based Nipah virus glycoprotein vaccines elicit potent protective immune responses in mice and hamsters., PMID:39293542
Isolation and characterization of IgG3 glycan-targeting antibodies with exceptional cross-reactivity for diverse viral families., PMID:39292703
An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection., PMID:39217188
Streamlined detection of Nipah virus antibodies using a split NanoLuc biosensor., PMID:39194145
Fully human single-domain antibody targeting a highly conserved cryptic epitope on the Nipah virus G protein., PMID:39134522
Measures to prevent and treat Nipah virus disease: research priorities for 2024-29., PMID:38964362
A highly effective ferritin-based divalent nanoparticle vaccine shields Syrian hamsters against lethal Nipah virus., PMID:38911870
Nano-Assembled Polyphosphazene Delivery System Enables Effective Intranasal Immunization with Nipah Virus Subunit Vaccine., PMID:38812435
A Luciferase Immunosorbent Assay Based on Attachment Glycoprotein for the Rapid and Easy Detection of Nipah Virus IgG Antibodies., PMID:38792812
A potent Henipavirus cross-neutralizing antibody reveals a dynamic fusion-triggering pattern of the G-tetramer., PMID:38773072
Evaluation of the immunogenicity of an mRNA vectored Nipah virus vaccine candidate in pigs., PMID:38726013
Structure and design of Langya virus glycoprotein antigens., PMID:38593070
Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates., PMID:38569014
Prefusion stabilization of the Hendra and Langya virus F proteins., PMID:38214525
Inactivated Recombinant Rabies Virus Displaying the Nipah Virus Envelope Glycoproteins Induces Systemic Immune Responses in Mice., PMID:38140162
Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8., PMID:38100536
Both chimpanzee adenovirus-vectored and DNA vaccines induced long-term immunity against Nipah virus infection., PMID:37925490
In silico prediction of interaction between Nipah virus attachment glycoprotein and host cell receptors Ephrin-B2 and Ephrin-B3 in domestic and peridomestic mammals., PMID:37924857
Predicting the changes in neutralizing antibody interaction with G protein derived from Bangladesh isolates of Nipah virus: molecular dynamics based approach., PMID:37643003
Recombinant Soluble Henipavirus Glycoprotein Preparation., PMID:37610572
Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV., PMID:37577376
Immunogenicity of poxvirus-based vaccines against Nipah virus., PMID:37452062
A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses., PMID:37243163
Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein., PMID:36932063
Development and laboratory evaluation of a competitive ELISA for serodiagnosis of Nipah and Hendra virus infection using recombinant Nipah glycoproteins and a monoclonal antibody., PMID:36816187
Establishment of a neutralization assay for Nipah virus using a high-titer pseudovirus system., PMID:36680637
Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate model., PMID:36508878
Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease., PMID:36445779
An Immunoinformatics Prediction of Novel Multi-Epitope Vaccines Candidate Against Surface Antigens of Nipah Virus., PMID:35761851
Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential., PMID:35759511
Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant., PMID:35617431
A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease., PMID:35286211
Architecture and antigenicity of the Nipah virus attachment glycoprotein., PMID:35239409
Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine., PMID:34956199
Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins., PMID:33927387
Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking., PMID:33106487
Vaccines to Emerging Viruses: Nipah and Hendra., PMID:32991264
Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development., PMID:32595632
For research use only. Not for human or drug use.
